US · ERNA
Ernexa Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 92121
- Website
- ernexatx.com
Price · as of 2024-12-31
$0.15
Market cap 2.24M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $102.01 | +66,791.8% |
| Intrinsic Value(DCF) | $1.74 | +1,040.98% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $4,800.00 | ||||
| 2016 | $4,236.00 | $27,786.25 | $0.00 | $0.00 | $29.38 |
| 2017 | $3,024.00 | $16,993.12 | $9.08 | $0.00 | $0.00 |
| 2018 | $2,082.00 | $1,890.43 | $34.84 | $70.16 | $0.00 |
| 2019 | $1,086.00 | $5,023.39 | $0.30 | $0.00 | $182.52 |
| 2020 | $2,352.00 | $4,469.15 | |||
| 2021 | $579.00 | ||||
| 2022 | $52.65 | ||||
| 2023 | $33.15 | $0.00 | $0.00 | ||
| 2024 | $4.35 | $102.01 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Ernexa Therapeutics Inc.'s (ERNA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $102.01
- Current price
- $0.15
- AI upside
- +66,791.8%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.74
+1,040.98% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ERNA | Ernexa Therapeutics Inc. | $0.15 | 2.24M | +66,792% | +1,041% | — | — | -2.77 | 72.62 | 212.25 | -3.39 | — | -360.15 | 83.51% | -2693.13% | -7652.75% | -2264.31% | -84.37% | -163.74% | 0.40 | -2.32 | 0.80 | 0.74 | 0.03 | -6152.00% | 75588.00% | -2067.00% | -13.12% | -5.39 | -87.22% | 0.00% | 0.00% | 28.59% | -7.81 | -7.56 | 210.46 | -50.59 |
| AEMD | Aethlon Medical, Inc. | $2.01 | 1.53M | — | — | — | — | -0.31 | 0.80 | — | 0.06 | -0.40 | 0.80 | 0.00% | — | — | -245.88% | -1215.78% | -171.58% | 0.13 | -924.06 | 3.13 | 2.90 | 0.37 | 7654.00% | — | -2635.00% | -185.54% | -4.03 | -995.06% | 0.00% | 0.00% | 8.49% | 0.08 | 0.10 | — | -34.37 |
| DWTX | Dogwood Therapeutics, Inc… | $2.85 | 5.45M | — | — | — | — | -0.55 | 0.11 | — | -0.61 | -0.71 | -0.51 | 0.00% | — | — | -36.28% | -37.33% | -25.08% | 0.24 | -132.63 | 5.21 | 4.67 | -0.06 | 7759.00% | — | 8049.00% | -129.59% | -2.77 | -26.84% | 0.00% | 0.00% | 0.01% | -0.62 | -0.86 | — | -1.22 |
| LNAI | Lunai Bioworks Inc. | $0.37 | 6.59M | — | — | — | — | -0.19 | -1.60 | — | -2.38 | -1.04 | -1.24 | 0.00% | — | — | -321.81% | -29.94% | -207.76% | -0.48 | -25.56 | 0.04 | 0.02 | -0.55 | 1846.00% | — | -2868.00% | -23.05% | -0.27 | -12.71% | 0.00% | 0.00% | 0.00% | -2.36 | -5.57 | — | -97.67 |
| MBRX | Moleculin Biotech, Inc. | $2.39 | 2.89M | — | — | — | — | -0.18 | 0.64 | — | 0.00 | — | -0.75 | 0.00% | — | — | -135.80% | -1009.89% | -78.93% | 0.08 | — | 0.97 | 0.80 | 0.14 | -5806.00% | — | -144.00% | -619.14% | -4.45 | -905.04% | 0.00% | 0.00% | 0.00% | 0.00 | 0.00 | — | -17.68 |
| MPLT | MapLight Therapeutics, In… | $17.27 | 13.63M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -83.21% | -1592.67% | -67.96% | 0.06 | — | 7.20 | 6.83 | 0.41 | 3955.00% | — | 5168.00% | — | -4.95 | -1528.13% | — | 0.00% | — | — | — | — | — |
| OSRH | OSR Holdings, Inc. | $0.41 | 10.58M | — | — | — | — | -5.08 | -1.58 | — | -3.39 | — | -1.58 | 0.00% | — | — | -15.54% | -21.87% | -10.39% | -0.27 | 81.95 | 0.07 | 0.01 | -0.48 | -85209.00% | — | 16722.00% | -21.32% | -0.33 | -15.79% | 0.00% | 0.00% | 0.00% | -3.39 | -5.47 | — | -12.68 |
| PMN | ProMIS Neurosciences, Inc… | $23.51 | 30.74M | — | — | — | — | 7.09 | 1.19 | — | 2.23 | — | 1.19 | 0.00% | — | — | 27.46% | 589.07% | 17.08% | 0.00 | -219.18 | 8.52 | 6.04 | -4.65 | -10775.00% | — | 15067.00% | -137.99% | -12.25 | 951.55% | 0.00% | 0.00% | 3.52% | -0.38 | -0.23 | — | -3.71 |
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
- CEO
- Sanjeev Luther
- Employees
- 6
- Beta
- 6.74
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.74 ÷ $0.15) − 1 = +1,040.98% (DCF, example).